Sign in
CompletedPhase 2

A Phase 2a Study of TAS5315 in Patients With Chronic Spontaneous Urticaria

Key facts

Who runs it
Taiho Pharmaceutical Co., Ltd.
Where
Japan12 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 2
People taking part
126 people enrolled
Started
28 Jun 2022
Ended
22 Dec 2023
Type of study
Interventional, 6 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • TAS5315 Dose 1
  • TAS5315 Dose 2
  • TAS5315 Dose 3
  • TAS5315 Dose 4
  • TAS5315 Dose 5
  • Placebo
Record updated
7 August 2024

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Aged 18 to 75 years
  • Diagnosis of chronic spontaneous urticaria (CSU)
  • Presence of itch and hives for at least 6 consecutive weeks prior to screening in spite of use of non-sedating H1-antihistamines for CSU
  • UAS7 score ≥ 16 and HSS7 score ≥ 8 during 7 days prior to study entry
  • In-clinic UAS ≥ 4 on study entry
  • Willing and able to complete and Participate Daily for the duration of the study

Who cannot take part

  • Treatment with omalizumab or other humanized anti-human IgE monoclonal antibody therapies used to treat CSU within 4 months prior to screening
  • Nonresponse to omalizumab or other humanized anti-human IgE monoclonal antibody therapies
  • Have been treated with other Bruton's Tyrosine Kinase inhibitors
  • Diseases other than CSU with symptoms of urticaria or angioedema, including urticarial vasculitis, erythema multiforme, mastocytosis, or hereditary or acquired angioedema
  • Atopic dermatitis, psoriasis, ichthyosis, or other skin disease associated with chronic itching
  • Bleeding diathesis
  • Uncontrolled hypertension disease states
  • Pregnant or lactating women

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The purpose of this study is to evaluate the efficacy and safety of TAS5315 in chronic spontaneous urticaria patients with an inadequate response to H1-antihistamines

The 6 groups in the trial

  • TAS5315 Dose 1Treatment being tested
  • TAS5315 Dose 2Treatment being tested
  • TAS5315 Dose 3Treatment being tested
  • AS5315 Dose 4Treatment being tested

    Treatment: TAS5315 Dose 4

  • TAS5315 Dose 5Treatment being tested
  • PlaceboPlacebo, for comparison

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 2a, Randomized, Double-blind, Study of TAS5315 in Chronic Spontaneous Urticaria Patients With an Inadequate Response to H1-antihistamines
Record updated
7 August 2024